Eric Dube, Travere Therapeutics CEO
June 2, 2026 09:55 AM EDT
DealsChinaPharma
Travere pays Everest $112M upfront to grow rare kidney disease pipeline
Kyle LaHucik
Travere pays Everest $112M upfront to grow rare kidney disease pipeline
Travere Therapeutics pays $112 million upfront to Everest Medicines for ex-China rights to BTK inhibitor civorebrutinib, targeting rare kidney diseases.
TL;DRAI
Travere Therapeutics acquisisce rare kidney disease pipeline da Everest per $112M upfront, diversificando terapie oltre Filspari. Consolidamento M&A biotech rare disease: partnership USA-China, nicchie alto margine, impatto su R&D strategy e valuazioni.
152 words~1 min read
